<DOC>
	<DOC>NCT02461290</DOC>
	<brief_summary>The primary objective is to evaluate the safety profile and tolerability of rituximab in combination with different chemotherapy regimens.</brief_summary>
	<brief_title>Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>New diagnosed Stage III/IV NHLs Grades 1, 2 follicular lymphoma need to be treated mCD20 positive Have an expected survival of 3 months or more ECOG 02 grade Normal renal function ALT less than double normal level Presence of CNS lymphoma Severe infectious disease or organic disease Having another malignant tumor Pregnant or breastfeeding female Organic heart disease, heart failure, II or higher grade AV bundle block. Subject is allergic to Rituximab Known HIV infection or chronic HBV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>